Jak2 V617F mouse complete blood count (CBC) testing is an essential hematological assay for characterizing myeloproliferative neoplasm (MPN) mouse models that carry the gain-of-function Jak2 V617F mutation. This testing service quantifies red blood cell, white blood cell, and platelet parameters in peripheral blood, providing critical data for disease phenotyping, monitoring MPN progression, and evaluating the efficacy of JAK inhibitors and other candidate therapeutics in preclinical studies.
Technical Overview
The Jak2 V617F mutation is a somatic gain-of-function mutation in exon 14 of the Janus kinase 2 (JAK2) gene, in which a valine residue at position 617 is substituted with phenylalanine. This mutation results in constitutive activation of the JAK-STAT signaling pathway, driving uncontrolled proliferation of hematopoietic progenitor cells. In humans, JAK2 V617F is detected in more than 95% of polycythemia vera patients and in approximately 50–60% of patients with essential thrombocythemia and primary myelofibrosis.
Mice engineered to express the Jak2 V617F mutation, including transgenic models, knock-in models, and bone marrow transplantation models, faithfully recapitulate the key features of human myeloproliferative neoplasms. These mice typically develop marked polycythemia, leukocytosis with neutrophilia, variable thrombocytosis, splenomegaly, extramedullary hematopoiesis, and progressive bone marrow fibrosis. Complete blood count (CBC) testing therefore serves as the primary and most informative endpoint for phenotyping these animals, tracking disease progression, and quantifying therapeutic responses in drug development programs.
Testing Samples
Peripheral Blood (Primary Sample)
EDTA-anticoagulated peripheral whole blood is the standard sample type for automated hematology analysis. Blood is collected from live mice for longitudinal monitoring or terminally for cross-sectional endpoint studies. Proper anticoagulation and prompt processing are essential to prevent platelet clumping and artifactual changes in cell counts.
Sample Collection Routes
- Tail vein nick or tail vein venipuncture for small-volume serial sampling
- Submandibular (facial) vein puncture for rapid collection without anesthesia
- Saphenous vein puncture for repeated low-volume sampling
- Retro-orbital sinus collection under general anesthesia, when larger volumes are required
- Terminal cardiac puncture or vena cava puncture for maximum yield at necropsy
Sample Volume and Handling Requirements
- Minimum volume: typically 20–50 µL for rodent-dedicated analyzers; 50–100 µL for standard automated analyzers
- Anticoagulant: K2-EDTA is preferred; heparin may interfere with staining and platelet morphology
- Processing window: analysis within 2–4 hours of collection is recommended
- Storage: if delayed, hold samples at 2–8 °C and analyze within 24 hours
- Reject criteria: gross hemolysis, microclots, insufficient volume, or delayed submission beyond validated stability limits
Testing Items
Red Blood Cell (Erythroid) Parameters
- Red blood cell count (RBC)
- Hemoglobin concentration (HGB)
- Hematocrit (HCT)
- Mean corpuscular volume (MCV)
- Mean corpuscular hemoglobin (MCH)
- Mean corpuscular hemoglobin concentration (MCHC)
- Red cell distribution width (RDW)
White Blood Cell (Leukocyte) Parameters
- Total white blood cell count (WBC)
- Absolute and relative neutrophil count
- Absolute and relative lymphocyte count
- Absolute and relative monocyte count
- Absolute and relative eosinophil count
- Absolute and relative basophil count
Platelet (Thrombocytic) Parameters
- Platelet count (PLT)
- Mean platelet volume (MPV)
- Platelet distribution width (PDW)
- Plateletcrit (PCT)
- Optional reticulocyte count for assessment of erythropoietic activity
Testing Methods
CBC analysis is performed on validated automated hematology analyzers equipped with rodent-specific software and species-appropriate reference channels. These instruments enumerate cells using impedance-based counting, laser light scatter, and flow cytometric principles, generating full CBC panels with five-part leukocyte differentials from microliter-scale blood volumes.
Automated results are supported by complementary methods when indicated. Wright-Giemsa-stained peripheral blood smears are prepared and reviewed microscopically to confirm the leukocyte differential, assess red cell and platelet morphology, and identify circulating immature myeloid or nucleated erythroid cells, which are characteristic of advanced disease in Jak2 V617F mice. Flow cytometric immunophenotyping can further resolve leukocyte subsets using lineage markers such as Gr-1/Ly6G, CD11b, CD3, CD19, and Ter119. Internal quality control materials, calibration verification, and replicate analysis ensure data accuracy, precision, and traceability across study cohorts.
Applications
- Phenotypic characterization of Jak2 V617F transgenic and knock-in mouse colonies, including genotype-phenotype correlation
- Longitudinal monitoring of MPN onset, progression, and terminal disease stages
- Preclinical efficacy evaluation of JAK inhibitors (such as ruxolitinib and fedratinib) and emerging targeted therapeutics
- Assessment of disease-modifying interventions on polycythemia, leukocytosis, and thrombopoiesis
- Supporting endpoints for splenomegaly, extramedullary hematopoiesis, and myelofibrosis studies
- Biomarker discovery and pharmacodynamic marker development in hematological research
- Investigation of clonal evolution, inflammation, and thrombosis mechanisms in myeloproliferative disease
FAQ
What CBC phenotype is expected in Jak2 V617F mice?
Affected mice characteristically show significantly elevated hematocrit, hemoglobin, and red blood cell counts, accompanied by leukocytosis dominated by neutrophilia. Platelet counts may be elevated, normal, or reduced depending on disease stage and genetic background. In late-stage disease, rising RDW, circulating immature cells, and worsening cytopenias may reflect progression toward myelofibrosis or leukemic transformation.
How much blood is required, and can live animals be tested repeatedly?
As little as 20–50 µL of blood is sufficient for rodent-configured analyzers. Serial sampling from the tail vein or submandibular vein permits longitudinal CBC monitoring in individual mice, provided cumulative blood volumes remain within animal welfare limits (typically no more than 10% of circulating volume per draw).
Which anticoagulant should be used?
K2-EDTA is the recommended anticoagulant for CBC testing. It preserves cell morphology and count stability. Heparin is generally avoided because it can interfere with staining quality and platelet aggregation measurements.
How quickly should samples be analyzed after collection?
Analysis within 2–4 hours of collection is ideal. If transport to the laboratory is required, samples should be kept at 2–8 °C and analyzed within 24 hours, as prolonged storage can cause artifactual swelling of red cells and altered differential counts.
How is therapeutic efficacy determined using CBC data?
Efficacy is evaluated by comparing hematological parameters between treated and vehicle-treated Jak2 V617F mice. A therapeutic response is indicated by normalization or significant reduction of elevated hematocrit, hemoglobin, and white blood cell counts, together with improvement in body weight, spleen size, and histopathological endpoints.
Can CBC testing be combined with other assays?
Yes. CBC testing is routinely integrated with genotyping PCR for mutation confirmation, flow cytometric immunophenotyping, serum erythropoietin measurement, cytokine profiling, spleen and bone marrow histopathology, and reticulin staining for myelofibrosis grading, providing a comprehensive hematological assessment package.